Cassava Sciences Inc (SAVA)

$49.06 3.35 (7.33%)

14:06 EDT SAVA Stock Quote Delayed 30 Minutes

Cassava Sciences: Fine Trading Stock, Terrible Investment

By Ian Bezek, InvestorPlace Contributor Oct 11, 2021

SAVA stock has fallen sharply in recent weeks. However, it's still a rather expensive bet on a controversial drug heading into Phase 3 trials.

Cassava Sciences Stock Could Explode as FDA Approval Is a Real Possibility

SAVA Stock Is a Buy Here Despite the Very Real Risks It Faces

Use Cassava Sciences Stock Weakness as Buy Opportunity Ahead of Phase 3

Volume:

Previous Close -

Market Cap 1.96B

PE Ratio -132.59

EPS -0.37

Volume (Avg. Vol.) 2.40M

Day's Range 45.39 - 49.50

52-Week Range 6.70 - 146.06

Dividend & Yield N/A (N/A)

SAVA Stock Predictions, Articles, and Cassava Sciences Inc News

From InvestorPlace
From the Web

What to Make of Cassava Sciences’ Late September Rally

By Will Ashworth, InvestorPlace Contributor Oct 4, 2021

Cassava Sciences gained 50% in the second half of September. Now the question is, can SAVA stock keep up momentum in October?

Cassava Stock Has Reached a Positive Turning Point

By Chris Lau, InvestorPlace Contributor Oct 1, 2021

Cassava is rebounding and SAVA stock may rally back to its old highs as it fends off a short-selling attack.

The Good News Is Piling Up for Cassava Stock

By Larry Ramer, InvestorPlace Contributor Oct 1, 2021

Recent news indicates that the FDA is going to reject a petition against Cassava, helping to make SAVA stock very attractive.

SAVA Stock: What Is Going on With Red-Hot Cassava Sciences Today?

By Chris MacDonald, InvestorPlace Contributor Sep 22, 2021

Today, Cassava Sciences initially soared on the announcement of some positive preliminary data, before SAVA stock began selling off.

Cassava Sciences Can Recover Despite Harsh Allegations

By Louis Navellier and the InvestorPlace Research Staff Sep 21, 2021

SAVA stock dove after a law firm made statements against the company. However, Cassava's CEO isn't just taking it lying down.

Cassava Sciences Has Value and Is Likely To Proceed to Phase 3

By Mark R. Hake, CFA Sep 17, 2021

SAVA stock still has an implied upside of 67.9% to $78 per share, even if there is a 50% chance that either the shorts or longs are right.

Cassava Stock Is a Bold Play That Could Pay Off Soon

By Chris Lau, InvestorPlace Contributor Sep 13, 2021

Bears are attacking Cassava as it questions the quality of its clinical data and try to stop its study for treating Alzheimer’s disease.

Cassava Sciences Stock Still Poses Risks After Absorbing Data Controversy

By Thomas Niel Sep 9, 2021

Simufilam's eventual approval is still uncertain. Its fading popularity among the Reddit set is a concern as well. Even after it 57%+ price haircut, approach SAVA stock cautiously.

7 Busted Biotech Stocks Due for a Rebound

By Chris Lau, InvestorPlace Contributor Sep 8, 2021

Buying biotech stocks while they're down is rewarding once they post positive clinical results, setting the stage for a big rally.

Fraud Allegations Are Unlikely to Keep Cassava Stock Down

By Larry Ramer, InvestorPlace Contributor Sep 3, 2021

Cassava's unchallenged safety and cognition data will result in the FDA allowing it to conduct a Phase 3 trial. SAVA stock is a buy.

Cassava Sciences Stock Will Fall Further on Data Manipulation Allegations

By Faizan Farooque Sep 2, 2021

SAVA stock is still one of the best performers this year, but the recent allegations mean shares will fall further as the story develops.

Wait to See How the Cassava Sciences Allegations Pan Out

By Will Ashworth, InvestorPlace Contributor Aug 31, 2021

Allegations have been leveled against Cassava Sciences. SAVA stock has fallen by more than 50% as a result. Is this a buy-on-the-dip moment?

Scrutiny Makes Cassava Sciences Stock a ‘Blood in the Street’ Opportunity

By Ian Cooper Aug 31, 2021

Cassava Sciences stock crashed after a lawyer sought to stop studies of the biotech’s experimental Alzheimer’s treatment. That just makes SAVA stock a better opportunity.